Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy has shown significant efficacy for relapsed or refractory (R/R) B-cell malignancies. Yet, CD19 CAR T cells fail to induce durable responses in most patients. Second infusions of CD19 CAR T cells (CART2) have been considered...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood Jg. 137; H. 3; S. 323
Hauptverfasser:	Gauthier, Jordan, Bezerra, Evandro D, Hirayama, Alexandre V, Fiorenza, Salvatore, Sheih, Alyssa, Chou, Cassie K, Kimble, Erik L, Pender, Barbara S, Hawkins, Reed M, Vakil, Aesha, Phi, Tinh-Doan, Steinmetz, Rachel N, Jamieson, Abby W, Bar, Merav, Cassaday, Ryan D, Chapuis, Aude G, Cowan, Andrew J, Green, Damian J, Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G, Riddell, Stanley R, Maloney, David G, Turtle, Cameron J
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 21.01.2021
Schlagworte:	Adult Aged Antigens, CD19 - metabolism Cell Proliferation Cyclophosphamide - therapeutic use Cytokine Release Syndrome - complications Female Humans Immunotherapy, Adoptive Leukemia, B-Cell - immunology Leukemia, B-Cell - therapy Leukemia, Lymphocytic, Chronic, B-Cell - immunology Leukemia, Lymphocytic, Chronic, B-Cell - therapy Lymphoma, Non-Hodgkin - immunology Lymphoma, Non-Hodgkin - therapy Male Middle Aged Multivariate Analysis Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Progression-Free Survival T-Lymphocytes - immunology Treatment Outcome Vidarabine - analogs & derivatives Vidarabine - therapeutic use
ISSN:	1528-0020, 1528-0020
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!